These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23756115)

  • 1. [Tetra-saccharide glucose as a diagnostic biomarker for Pompe disease: a study with 35 patients].
    Bobillo Lobato J; Durán Parejo P; Tejero Díez P; Jiménez Jiménez LM
    Med Clin (Barc); 2013 Aug; 141(3):106-10. PubMed ID: 23756115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The decision-making levels of urine tetrasaccharide for the diagnosis of Pompe disease in the Turkish population.
    Canbay E; Vural M; Kalkan Uçar S; Sezer ED; Karasoy H; Yüceyar AN; Çoker M; Sözmen EY
    J Pediatr Endocrinol Metab; 2020 Mar; 33(3):391-395. PubMed ID: 32069240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease.
    An Y; Young SP; Kishnani PS; Millington DS; Amalfitano A; Corz D; Chen YT
    Mol Genet Metab; 2005 Aug; 85(4):247-54. PubMed ID: 15886040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine analysis of glucose tetrasaccharide by HPLC; a useful marker for the investigation of patients with Pompe and other glycogen storage diseases.
    Manwaring V; Prunty H; Bainbridge K; Burke D; Finnegan N; Franses R; Lam A; Vellodi A; Heales S
    J Inherit Metab Dis; 2012 Mar; 35(2):311-6. PubMed ID: 21687968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques.
    Young SP; Piraud M; Goldstein JL; Zhang H; Rehder C; Laforet P; Kishnani PS; Millington DS; Bashir MR; Bali DS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):50-8. PubMed ID: 22252961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease.
    An Y; Young SP; Hillman SL; Van Hove JL; Chen YT; Millington DS
    Anal Biochem; 2000 Dec; 287(1):136-43. PubMed ID: 11078593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker.
    Young SP; Zhang H; Corzo D; Thurberg BL; Bali D; Kishnani PS; Millington DS
    Genet Med; 2009 Jul; 11(7):536-41. PubMed ID: 19521244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined targeted and untargeted high-resolution mass spectrometry analyses to investigate metabolic alterations in pompe disease.
    de Moraes MBM; de Souza HMR; de Oliveira MLC; Peake RWA; Scalco FB; Garrett R
    Metabolomics; 2023 Mar; 19(4):29. PubMed ID: 36988742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid ultraperformance liquid chromatography-tandem mass spectrometry assay for a characteristic glycogen-derived tetrasaccharide in Pompe disease and other glycogen storage diseases.
    Sluiter W; van den Bosch JC; Goudriaan DA; van Gelder CM; de Vries JM; Huijmans JG; Reuser AJ; van der Ploeg AT; Ruijter GJ
    Clin Chem; 2012 Jul; 58(7):1139-47. PubMed ID: 22623745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative computed tomography for enzyme replacement therapy in Pompe disease.
    Yonee C; Toyoshima M; Young SP; Maruyama S; Higuchi I; Narita A; Maegaki Y; Nanba E; Ohno K; Kawano Y
    Brain Dev; 2012 Nov; 34(10):834-9. PubMed ID: 22521436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of oligosaccharides in Pompe disease by electrospray ionization tandem mass spectrometry.
    Rozaklis T; Ramsay SL; Whitfield PD; Ranieri E; Hopwood JJ; Meikle PJ
    Clin Chem; 2002 Jan; 48(1):131-9. PubMed ID: 11751548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods of diagnosis of patients with Pompe disease: Data from the Pompe Registry.
    Kishnani PS; Amartino HM; Lindberg C; Miller TM; Wilson A; Keutzer J
    Mol Genet Metab; 2014; 113(1-2):84-91. PubMed ID: 25085280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a kit for urine collection on filter paper as an alternative for Pompe disease screening and monitoring by LC-HRMS.
    de Souza HMR; Scalco FB; Garrett R; de C Marques FF
    Anal Methods; 2023 Aug; 15(32):3932-3939. PubMed ID: 37539791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HPLC analysis of oligosaccharides in urine from oligosaccharidosis patients.
    Peelen GO; de Jong JG; Wevers RA
    Clin Chem; 1994 Jun; 40(6):914-21. PubMed ID: 8087986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oligosaccharide analysis in urine by maldi-tof mass spectrometry for the diagnosis of lysosomal storage diseases.
    Xia B; Asif G; Arthur L; Pervaiz MA; Li X; Liu R; Cummings RD; He M
    Clin Chem; 2013 Sep; 59(9):1357-68. PubMed ID: 23676310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of acid alpha-glucosidase and glycogen content in skin fibroblasts with age of onset in Pompe disease.
    Umapathysivam K; Hopwood JJ; Meikle PJ
    Clin Chim Acta; 2005 Nov; 361(1-2):191-8. PubMed ID: 15993875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nosology of lysosomal glycogen storage diseases without in vitro acid maltase deficiency. Delineation of a neonatal form.
    Verloes A; Massin M; Lombet J; Grattagliano B; Soyeur D; Rigo J; Koulischer L; Van Hoof F
    Am J Med Genet; 1997 Oct; 72(2):135-42. PubMed ID: 9382133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for Pompe disease using a rapid dried blood spot method: experience of a clinical diagnostic laboratory.
    Goldstein JL; Young SP; Changela M; Dickerson GH; Zhang H; Dai J; Peterson D; Millington DS; Kishnani PS; Bali DS
    Muscle Nerve; 2009 Jul; 40(1):32-6. PubMed ID: 19533645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remarkably low fibroblast acid α-glucosidase activity in three adults with Pompe disease.
    Wens SC; Kroos MA; de Vries JM; Hoogeveen-Westerveld M; Wijgerde MG; van Doorn PA; van der Ploeg AT; Reuser AJ
    Mol Genet Metab; 2012 Nov; 107(3):485-9. PubMed ID: 23000108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of urinary oligosaccharide excretion patterns by UHPLC/HRAM mass spectrometry for screening of lysosomal storage disorders.
    Hagemeijer MC; van den Bosch JC; Bongaerts M; Jacobs EH; van den Hout JMP; Oussoren E; Ruijter GJG
    J Inherit Metab Dis; 2023 Mar; 46(2):206-219. PubMed ID: 36752951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.